Net Loss per Common Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss per Common Share

12. Net Loss per Common Share

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:

	March 31,
	2024		2023
Stock options outstanding		6,892,951		5,706,777
Unvested restricted stock awards and units		3,110,597		5,747,172
Shares reserved for future issuance		1,649,038		600,127
Apexigen replacement warrants		1,003,191		—
Employee stock purchase plan		675,485		644,755
Total		13,331,262		12,698,831

Pre-Funded Warrant Shares of 1,611,215 shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants are issuable for nominal consideration.